Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Stem Cell Therapy for Tissue Regeneration

Stem Cell Therapy for Tissue Regeneration

Stem cell therapy is a method used in regenerative medicine to repair and restore function to damaged tissues and organs. Stem cells have the potential to proliferate and differentiate into various tissue types, making them ideal candidates for tissue regeneration. For example, hematopoietic stem cell transplants are commonly used in blood cancer treatment to replenish damaged bone marrow and restore healthy blood cells.
Types of Stem Cells used in Stem Cell Therapy
The two main cell...

Heart Failure VI: Adjunct Therapies

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.

Cardiomyopathy V: Interprofessional Care

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...

Heart Failure II: Pathophysiology

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...

Cardiomyopathy II: Dilated Cardiomyopathy

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Age and sex specific coronary plaque characteristics among South Asians: Insights from the DILWALE CTA study.

American journal of preventive cardiology·2026

Same authorSame journal

Beyond LDL-C: Triangulating residual risk via lipoprotein(a), remnant cholesterol, and vascular inflammation.

Progress in cardiovascular diseases·2026

Same author

Primary Prevention of Dyslipidemia: 10 Practice-Changing Takeaways from the 2026 ACC/AHA Multisociety Guideline.

Current atherosclerosis reports·2026

Same author

Highlights of Cardiovascular Disease Prevention Studies Presented at the 2026 American College of Cardiology Conference.

Current atherosclerosis reports·2026

Same author

Diagnostic Performance of Two CCTA Derived Noninvasive FFR Techniques: The TripleFFR Study.

Circulation. Cardiovascular imaging·2026

Same author

Global Burden of Cardiovascular Disease: What Should Be Expected in the Next 25 Years?

Current cardiology reports·2026

Search research articles

Related Experiment Video

Updated: Sep 10, 2025

Cell-based Therapy for Heart Failure in Rat: Double Thoracotomy for Myocardial Infarction and Epicardial Implantation of Cells and Biomatrix

Cell-based Therapy for Heart Failure in Rat: Double Thoracotomy for Myocardial Infarction and Epicardial Implantation of Cells and Biomatrix

Published on: September 22, 2014

Cell therapy for heart failure -recent progress and future directions.

Roberto Bolli¹, Joshua M Hare², Emerson C Perin³

¹Division of Cardiology, University of Louisville, Louisville, KY, United States of America.

Progress in Cardiovascular Diseases

|August 27, 2025

Summary

This summary is machine-generated.

Cell therapy shows promise for treating heart failure (HF), with mesenchymal stromal cells (MSCs) demonstrating safety and potential benefits in clinical trials. Further large-scale studies are needed to confirm efficacy and establish cell therapy as a viable HF treatment option.

Keywords:

Stem cells cardiac regeneration cardiac repair heart failure

More Related Videos

Isolation, Characterization, and Differentiation of Cardiac Stem Cells from the Adult Mouse Heart

Isolation, Characterization, and Differentiation of Cardiac Stem Cells from the Adult Mouse Heart

Published on: January 7, 2019

Establishing a Swine Model of Post-myocardial Infarction Heart Failure for Stem Cell Treatment

Establishing a Swine Model of Post-myocardial Infarction Heart Failure for Stem Cell Treatment

Published on: May 25, 2020

Related Experiment Videos

Last Updated: Sep 10, 2025

Cell-based Therapy for Heart Failure in Rat: Double Thoracotomy for Myocardial Infarction and Epicardial Implantation of Cells and Biomatrix

Cell-based Therapy for Heart Failure in Rat: Double Thoracotomy for Myocardial Infarction and Epicardial Implantation of Cells and Biomatrix

Published on: September 22, 2014

Isolation, Characterization, and Differentiation of Cardiac Stem Cells from the Adult Mouse Heart

Isolation, Characterization, and Differentiation of Cardiac Stem Cells from the Adult Mouse Heart

Published on: January 7, 2019

Establishing a Swine Model of Post-myocardial Infarction Heart Failure for Stem Cell Treatment

Establishing a Swine Model of Post-myocardial Infarction Heart Failure for Stem Cell Treatment

Published on: May 25, 2020

Area of Science:

Regenerative Medicine
Cardiology
Cell Biology

Background:

Heart failure (HF) prevalence is rising globally, posing a significant public health challenge.
Current treatments for HF have limitations, necessitating novel therapeutic strategies.
Cell therapy has emerged as a promising approach to improve HF outcomes.

Purpose of the Study:

To review the progress and future directions of cell therapy for heart failure.
To summarize the safety and efficacy data of various cell types in HF treatment.
To explore novel cell types and delivery strategies for enhanced HF therapy.

Main Methods:

Review of existing literature on cell therapy for HF.
Analysis of safety data from numerous studies and randomized controlled trials.
Evaluation of clinical outcomes from trials using mesenchymal stromal cells (MSCs).

Main Results:

Cell therapy, particularly with MSCs, has demonstrated a strong safety profile in HF patients.
Several trials indicate beneficial effects of cell therapy on clinical outcomes in cardiomyopathy.
Ongoing trials are investigating new cell types and delivery methods, such as repeated doses and intravenous delivery.

Conclusions:

Cell therapy holds significant potential as a future treatment for heart failure.
Robust safety data and promising efficacy signals warrant further large-scale clinical trials.
Continued research into novel cell types and strategies may optimize cell therapy for HF management.